70 related articles for article (PubMed ID: 17997118)
1. [The impact of 3D image guided prostate brachytherapy on therapeutic ratio: the Quebec University Hospital experience].
Foster W; Beaulieu L; Harel F; Martin AG; Vigneault E
Cancer Radiother; 2007 Dec; 11(8):452-60. PubMed ID: 17997118
[TBL] [Abstract][Full Text] [Related]
2. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
3. Comparison of preplanning and intraoperative planning for I-125 prostate brachytherapy.
Yoshida K; Ohashi T; Yorozu A; Toya K; Nishiyama T; Saito S; Hanada T; Shiraishi Y; Shigematsu N
Jpn J Clin Oncol; 2013 Apr; 43(4):383-9. PubMed ID: 23315386
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
6. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
7. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
8. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
9. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.
Zamboglou N; Tselis N; Baltas D; Buhleier T; Martin T; Milickovic N; Papaioannou S; Ackermann H; Tunn UW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):672-8. PubMed ID: 22929859
[TBL] [Abstract][Full Text] [Related]
11. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy boost to the dominant intra-prostatic tumor region: hemi-irradiation of prostate cancer.
Schick U; Popowski Y; Nouet P; Bieri S; Rouzaud M; Khan H; Weber DC; Miralbell R
Prostate; 2011 Sep; 71(12):1309-16. PubMed ID: 21308714
[TBL] [Abstract][Full Text] [Related]
13. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
Zelefsky MJ; Yamada Y; Cohen GN; Shippy A; Chan H; Fridman D; Zaider M
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):65-70. PubMed ID: 17189063
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
[TBL] [Abstract][Full Text] [Related]
15. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Saito S; Nishiyama T; Yagi Y; Shigematsu N
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1069-75. PubMed ID: 25539368
[TBL] [Abstract][Full Text] [Related]
16. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
17. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
18. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
[TBL] [Abstract][Full Text] [Related]
19. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup.
Koutrouvelis PG; Lailas N; Katz S; Sehn J; Gil-Montero G; Khawand N
J Urol; 2003 Apr; 169(4):1331-6. PubMed ID: 12629354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]